Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,221
datasets available to search
ShareScore release 0.9.0
Dataset results
6,221 results for “Cancer therapy”
RNA datasets to derive predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer
<p>Nanostring nCounter datasets and corresponding clinical data of tumor samples of patients with advanced NSCLC who received anti-PD-1 immuntherapy. Prospectively divided into a discovery and a validation cohort.</p> <p>Please cite the corresponding publication in Annals of Oncology (10.1093/annonc/mdz049)</p>
Multi-omic machine learning predictor of breast cancer therapy response
<p>H&E slides used in the training dataset described in "Multi-omic machine learning predictor of breast cancer therapy response" published in <em>Nature</em>: <a href="https://www.nature.com/articles/s41586-021-04278-5">https://www.nature.com/articles/s41586-021-04278-5</a></p> <p>Metadata associated with these images also included in file Slide metadata.xlsx</p>
Conventional therapy induces tumor immunoediting and modulates the immune contexture in colorectal cancer
<p>Cancer immunotherapies for patients with colorectal cancer (CRC) continue to lag behind other solid cancer types with the exception of 4% of patients with microsatellite-instable tumors. Thus, there is an urgent need to broaden the clinical benefit of checkpoint blockers to CRC by combining conventional therapies to sensitize tumors to immunotherapy. However, the impact of conventional drugs on immunoediting and hence, imposing positive selection towards less immunogenic variants, and on the tumor immune contexture in CRC remains elusive.</p> <p>In this study, we performed comprehensive multimodal profiling using longitudinal samples from metastatic CRC patients undergoing neoadjuvant therapy with mFOLFOX6 and Bevacizumab. Exome-sequencing, RNA-sequencing and multiplexed immunofluorescence imaging was carried out on tumor samples obtained before and after therapy and the data was analyzed using established methods. The results of the analysis were extrapolated to publicly available datasets (TCGA and CPTAC). In order to identify a surrogate marker, an explainable artificial intelligence method was developed using a transformer-based analytical pipeline for the identification of features in H&E images associated with specific biological processes, followed by manual evaluation of highly informative tiles by a pathologist.</p> <p>We expect that the results of this project will provide a deeper understanding of the tumor-immune interactions and will allow the development of more robust combinatorial therapeutic strategies for MSS CRC.</p>
Clonal heterogeneity of endocrine therapy resistance in breast cancer
<p>We barcoded endocrine therapy sensitive cell lines (MCF7 and T47D) and rendered them resistant to commonly applied first line endocrine therapeutics (Tamoxifen and estrogen deprivation). Next, we isolated single cell clones of endocrine therapy resistant populations and subjected clonal cell lines to RNA-Seq and Phosphoproteomics profiling.</p>
Associated code and data for "Multi-level computational modeling of anti-cancer dendritic cell vaccination utilized to select molecular targets for therapy optimization (doi: 10.3389/fcell.2021.74635)"
<p>This deposit contains the data, code, and analysis to reproduce the results in the manuscript - Lai X, Keller C, Santos-Rosales G, Schaft N, Dörrie J, Vera J. Multi-level computational modeling of anti-cancer dendritic cell vaccination utilized to select molecular targets for therapy optimization. Frontiers in Cell and Developmental Biolology. 2022; 9:746359; <a href="https://www.researchgate.net/publication/358461035_Multi-Level_Computational_Modeling_of_Anti-Cancer_Dendritic_Cell_Vaccination_Utilized_to_Select_Molecular_Targets_for_Therapy_Optimization">doi:10.3389/fcell.2021.746359</a>.</p> <p>If you have used the code for your research, please cite the original publication. Thank you very much.</p> <p> </p>
Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy
<p>Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment. However, only a fraction of the patients respond to ICB therapy. Accurate prediction of patients to likely respond to ICB would maximize the efficacy of ICB therapy. The tumor microenvironment (TME) dictates tumor progression and therapy outcome. Here, we classify the TME by analyzing the transcriptome from 11,069 cancer patients based on angiogenesis and T-cell activity. We find three distinct angio-immune TME subtypes conserved across 30 non-hematological cancers. There is a clear inverse relationship between angiogenesis and anti-tumor immunity in TME. Remarkably, patients displaying TME with low angiogenesis with strong anti-tumor immunity show the most significant responses to ICB therapy in four cancers. Re-evaluation of the renal cell carcinoma clinical trials provides compelling evidence that the baseline angio-immune state is robustly predictive of ICB responses. This study offers a rationale for incorporating baseline angio-immune scores for future ICB treatment strategies.</p>
Supplementary material - Non-invasive Multimodal Imaging Reveals Early Therapy-Induced Senescence in Human Cancer Cells
<p>The repository features .xls and .txt worksheets including all the data used through this work and reported in the manuscript figures and graphs. More precisely, we included the following: </p> <ul> <li>Figure 2. Raw pixel-wise signals detected in NLO images of TIS cells control cells that were used to perform the colocalization graphs and analyses reported. We describe the average colocalization of SRS and F-CARS signals, and TPEF and E-CARS signals, in both phenotypes.</li> <li>Figure 4. Raw data from image analyses of TPEF and SRS channels of multimodal NLO images, divided in 5 different time points over the therapy follow-up period. The data describe the early rearrangement of mitochondria (TPEF) and lipid vesicles (SRS) in TIS cells, with respect to control counterparts.</li> <li>Figure 6. Raw data from image analyses of QPI images, divided in 4 different time points over the therapy follow-up period. The data describe the early morphological modifications of TIS cells, with respect to control counterparts.</li> </ul>
Dataset on prognostic factors in patients with metastatic castration-resistant prostate cancer undergoing radioligand therapy with [177Lu]Lu-PSMA-617
<p>This upload provides Open Data associated with the publication "Prognostic value of the De Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy" by Gaal S <em>et al.</em> (2023).</p> <p>The upload contains the anonymized dataset of 91 patients analyzed in this publication with all variables that are required to reproduce the results.</p> <p>However, to fully comply with requirements for data anonymization, the patients' age was categorized into groups spanning 5 years each. A dataset with the age variable in exact years can be obtained from the corresponding author (julian.rogasch@charite.de) upon reasonable request.</p> <p>Besides the dataset, this upload provides a dictionary to explain all variables and their categories.</p>
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
ClinicalTrials.gov study NCT04478266. IPD Sharing: YES. Countries: 30. Publications: 2.
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
ClinicalTrials.gov study NCT02975934. IPD Sharing: YES. Countries: 12. Publications: 3.
Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
ClinicalTrials.gov study NCT03837496. IPD Sharing: YES. Countries: 1. Publications: 3.
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
ClinicalTrials.gov study NCT01852292. IPD Sharing: UNDECIDED. Countries: 18. Publications: 2.
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
ClinicalTrials.gov study NCT00721799. IPD Sharing: NO. Countries: 1. Publications: 3.
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
ClinicalTrials.gov study NCT03759587. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
ClinicalTrials.gov study NCT05104567. IPD Sharing: YES. Countries: 9. Publications: 0.
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ClinicalTrials.gov study NCT04689828. IPD Sharing: YES. Countries: 14. Publications: 2.
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
ClinicalTrials.gov study NCT03078751. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
ClinicalTrials.gov study NCT03626545. IPD Sharing: YES. Countries: 26. Publications: 1.
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
ClinicalTrials.gov study NCT04879849. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
ClinicalTrials.gov study NCT03983382. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.